现实生活中的经验,索拉费尼布用于晚期和耐火的desmoid类型纤维素瘤
Delphine Schampers1, Alexander Decruyenaere2, Celine Jacobs2
1Department of medical oncology, Ghent University Hospital, Ghent, Belgium. delphine.schampers@ugent.be.
Acta oncologica (Stockholm, Sweden)
|August 5, 2024
概括
索拉费尼布在治疗渐进性desmoid型纤维素瘤 (DF) 中表现出有效性,具有显著的毒性,需要频繁降低剂量. 现实世界的数据支持其在临床实践中的使用.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
背景情况:
- 德斯莫伊德型纤维素瘤 (DF) 治疗已经转向警等待,而不是局部疗法.
- 对DF的全身治疗只适用于渐进或有症状的病例.
研究的目的:
- 审查关于索拉费尼布在desmoid类型纤维素瘤中使用的真实数据.
- 在临床环境中评估索拉费尼布的疗效和毒性.
主要方法:
- 对治疗索拉费尼布治疗渐进性DF的患者的回顾性分析.
- 评估患者的人口结构,疾病特征,治疗反应 (RECIST 1.1),以及毒性 (CTCAE v5.0).
主要成果:
- 11名患者接受了索拉费尼布;36.4%的部分反应,54.5%的病情稳定.
- 平均治疗持续时间为20.4个月;中位时间到反应为15.0个月.
- 高水平的毒性 (81.8%级2,36.4%级3),主要与皮肤有关,需要减少81.8%的患者的剂量.
结论:
- 现实世界的索拉费尼布数据与DF的临床试验结果一致.
- 索拉费尼布是一种有效的系统选择,用于渐进的DF.
- 显著的毒性需要谨慎管理和剂量调整.
更多相关视频
07:15A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
9.6K
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
2.3K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...